Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi-aventis - ticlopidine hydrochloride - tablet - 250 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

gulf pharmaceutical industries (julphar) - ticlopidine hydrochloride - film-coated tablet - 250 mg

Singapore - English - HSA (Health Sciences Authority)

ziwell medical (s) pte ltd - ticlopidine hcl - tablet, sugar coated - ticlopidine hcl 250 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - ticlopidine 250 mg - 250 mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

impexeco sa-nv - ticlopidine hydrochloride 250 mg - film-coated tablet - ticlopidine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma sa-nv - ticlopidine hydrochloride 250 mg - film-coated tablet - ticlopidine

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - ticlopidine hcl - tablet, film coated - 250 mg

European Union - English - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antithrombotic agents - xarelto, co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bivalirudin, quantity: 250 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide - bivalirudin is indicated for use as an anticoagulant: ? in the treatment of patients with moderate to high risk acute coronary syndromes (acs) (unstable angina/non-st segment elevation myocardial infarction (ua/nstemi) who are undergoing early invasive management, and ? in patients undergoing percutaneous coronary intervention (pci). bivalirudin is intended for use with aspirin. a p2y12 antagonist (e.g. clopidogrel or ticlopidine) may be used in addition to aspirin.

Australia - English - Department of Health (Therapeutic Goods Administration)

sciclone pharmaceuticals pty ltd - bivalirudin, quantity: 250 mg - injection, powder for - excipient ingredients: sodium hydroxide; mannitol - angiomax is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (pci). angiomax is intended for use with aspirin.,angiomax is indicated for use as an anticoagulant: in the treatment of patients with moderate to high risk acute coronary syndromes (acs) [unstable angina/non-st segment elevation myocardial infarction (ua/nstemi) who are undergoing early invasive management, and in patients undergoing percutaneous coronary intervention (pci). angiomax is intended for use with aspirin. a p2y12 antagonist (eg clopidogrel or ticlopidine) may be used in addition to aspirin.